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OBJECTIVES: To reduce the increase of the expenditure in disease-modifying drugs
(DMD) used in the first line treatment of remitting-relapsing multiple sclerosis
(RRMS) by forcing a decrease in the price of drugs, as a consequence of the intro-
duction of competition mechanisms. METHODS: By the second half of 2009, the
first biosimilar drug of beta-interferon (bIFN)-1b Betaferon® (Extavia®), gained ac-
cess to the Spanish market, and as a consequence of the acquisition public contest
set up by our hospital, Extavia® was selected, with 7% discount. At that time,
bIFN-1b was used in about 40% of RRMS patients treated in first line. By the end of
2010, the Pharmacy Comitee evaluated the different DMD, taking as starting an
Andalussian Agency for Health Technology Assessment report, and stated that
bIFN-1a sc (44 mg), bIFN-1b and Glatiramer acetate were therateutic equivalents for
the initial treatment of RRMS. An open contest was announced to select the drug to
be used as first line treatment. The lowest therapeutic equivalent daily treatment
cost was selection criterion. All new patients were commenced on the drug se-
lected. A comitee composed by the Medical Manager and the heads of the Neurol-
ogy and the Pharmacy departments assesses the requests for treatment in each
case. The cost difference between the selected treatment and average cost before
the evaluation was multiplied by the total number of new patients to calculate
savings generated. RESULTS: Overall, cost per patient was reduced by 4.5% when
Extavia® was selected as bIFN-1b. When, in a second step, bIFN-1b was designated
as first line drug for RRMS, cost per patient decreased by an additional 7%. A total of
150,000 € (one year) was saved as a result of this strategy. CONCLUSIONS: Thera-
peutic equivalence offers a sound means to improve the efficiency beyond that
obtained with biosimilar drugs, especially in high cost drugs used in chronic ill-
nesses.
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OBJECTIVES: Patients with Alzheimer’s disease (AD) show a high incidence of be-
havioral and psychological symptoms of dementia (BPSD), which often lead to the
prescription of antipsychotics. The objective of the present study was to assess the
impact of the initiation of memantine or cholinesterase inhibitors (ChEIs) on the
use of antipsychotics. METHODS: Patients covered by the Quebec provincial drug
reimbursement program (RAMQ) who had a diagnosis of AD and were initial users
of memantine or ChEIs in the period from January 2005 to March 2011 were se-
lected. The proportion of patients who used antipsychotic drugs was estimated
using prescription data dating back up to 1 year before and up to 1 year after the
first prescription of memantine or ChEIs. For each month in the year before and
after initiation of memantine or ChEIs, the proportion of patients who used an
antipsychotic was estimated. The difference between the slopes corresponding to
the periods pre- and post-memantine or ChEIs were analyzed using an interrupted
time series (ITS) design. RESULTS:Of the random sample of 21,716 patients, 8.9% (n
1,929) initiated memantine whereas 91.1% (n 19,787) initiated a ChEI. The per-
centage of antipsychotics users increased by 118.3% before and by 68.3% after
initiation of a ChEI, and increased by 68.6% before and by 7.0% after initiation of
memantine. According to the ITS analysis, antipsychotics trends pre- and post-
ChEI initiation were not statistically different (P 0.89) while a statistical difference
was observed when comparing the antipsychotics trends pre- and post- meman-
tine initiation (P 0.001). CONCLUSIONS: The initiation of memantine, unlike
ChEIs, has a notable stabilization effect on the prescription of antipsychotics in AD
patients. Given the concerns associated with the use of antipsychotics in AD pa-
tients, initiation of memantine could be considered as a relevant alternative to
alleviate BPSD.
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OBJECTIVES: Examine number of hospitalizations, length of stay and costs among
patients diagnosed with Parkinson’s Disease initiating therapy with either a dopa-
mine agonist (DA) or Rasagiline. METHODS: This study utilized data from the Mar-
ketScan Medicare Supplemental Database from 2/1/2006 through 12/31/2011. Pa-
tients were prescribed Rasagiline or a DA, with first such date identified as index
date, were diagnosed with PD in the 3 years post index date (e.g., the post-period),
had continuous insurance coverage from 6 months prior (e.g., the pre-period)
through the end of the post-period, and were at least 65 years old. The odds or
hospitalization were estimated using logistic regression, while hospital length of
stay (LOS) and number of hospitalizations were estimated using negative binomial
regressions. The costs associated with hospitalizations were estimated from a two
part multivariate model where the first part estimated the probability of being
hospitalized and the second part estimated costs among those hospitalized.
RESULTS: There were 7,230 individuals in the analyses (5,886DA; 1,234 Rasagiline).
The mean age was 76 years and most were male (58.40%), resided in the North
Central (33.71%) or Southern (30.14%) regions of the US and were insured via com-
prehensive (48.42%) or preferred provider organization (36.06%) supplemental in-
surance. After controlling for patient characteristics, general health, disability sta-
tus, comorbid diagnoses, and index prescription characteristics, Rasagiline,
compared to DA, was associated with a significantly lower probability of being
hospitalized in the post-period (OR0.755; 95% CI 0.663 – 0.860), significantly fewer
hospitalizations (-0.21; P0.0001) and shorter LOS (-0.38 days; P0.0001) compared
to individuals who initiated on a DA. Furthermore, total costs associated with
hospitalizations were 24% lower among patients who initiated on Rasagiline
($12,327 v $16,525; P0.0001) compared to initiators on a DA. CONCLUSIONS:
Among patients with PD, initiation with Rasagiline compared to a DA is associated
with significantly improved hospitalization outcomes.
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OBJECTIVES: Qualitative interview aimed to develop a PRO questionnaire that al-
lows assessment of HAE acute attacks. METHODS: Open-ended qualitative inter-
views were performed with HAE patients in Argentina (n10) and the US (n33);
these data were used to develop the first draft questionnaire. Subsequently, more
in-depth qualitative interviews were performed with HAE patients in the UK
(n10), Brazil (n10), Germany (n11) and France (n12). Patients who had expe-
rienced abdominal, cutaneous or laryngeal attacks of varying severity levels were
recruited. Patients initially discussed their experience of HAE attack symptoms,
impacts and treatments in an open-ended manner. Cognitive debriefing of the PRO
was then performed to assess patient understanding and relevance of question-
naire items. RESULTS: Most commonly reported abdominal attack symptoms in-
clude pain, vomiting, stomach swelling, diarrhoea and nausea. Cutaneous attacks
caused skin swelling, pain and redness. Laryngeal attacks led to difficulty breath-
ing, voice change and difficulty swallowing. Patients also discussed attack triggers,
warning signs, impacts and treatment options. Elicited concepts were mapped
onto the PRO, which was revised to include all aspects of importance to HAE pa-
tients. Cognitive debriefing aided in the revision of the questionnaire.
CONCLUSIONS: Data from the qualitative interviews were used to develop an ex-
panded conceptual model capturing all aspects of HAE. The PRO was revised to
ensure all concepts of importance to HAE are captured. The questionnaire can be
considered a valid tool for the long term assessment of the HAE patients.
PND70
PATIENT CHARACTERISTICS AND TREATMENT STATUS IN PARKINSON’S
DISEASE (PD)
Grubb E1, Castelli-Haley J1, Treglia M2, Lage MJ2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray
Beach, FL, USA
OBJECTIVES: Examine patient characteristics and predictors of treatment in U.S.
patients with PD. METHODS: Data were obtained from MarketScan between 1/1/
2006 and 3/30/2011. Selected patients were diagnosed with PD, with initial diagno-
sis date identified as index date. Each subject was at least 35 years old and had
continuous insurance coverage from 6 months prior through 12 months post index
date. Descriptive analysis of patient characteristics compared differences in con-
tinuous variables using t-tests and categorical variables using chi-square statistics.
Logistic regression examined predictors of treatment. The pre-specified level of
statistical significance was 5%. RESULTS: There were 9,423 subjects who met study
criteria. Most (n  5,541, 58.8%) were treated with pharmacotherapy. Treated indi-
viduals were older than untreated (57.1 vs. 56.0 years, p0.0001), more likely to be
male (p0.0035), more likely to reside in the south and less likely to reside in the
northeast (p0.0001). In general, the treated cohort tended to be in poorer health
and have greater disability. The treated were more likely to have been diagnosed by
a neurologist and there were differences in the types of health insurance plans in
which they were enrolled. The logistic analysis examining predictors of treatment
revealed odds ratios (point estimate; 95% CL) for filling a PD prescription were
higher with age (1.03; 1.023 - 1.037), medical ADL (1.349; 1.170 - 1.556) or muscular
skeletal (1.467; 1.329-1.618) disability, prior comorbid disease, diagnosis by a neu-
rologist relative to a GP (1.385; 1.228 – 1.561), and being enrolled in either a POS
(1.524; 1.264 – 1.837) or PPO (1.151; 1.024 – 1.293) health plan. Factors associated with
a lower likelihood of being treated included being female (0.852; 0.780 – 0.930),
region of residence, and higher Charlson Comorbidity Score (0.915; 0.877 – 0.955).
CONCLUSIONS: These analyses highlighted potential age, gender and access dis-
parities in receipt of treatment for PD.
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OBJECTIVES: Examine patient characteristics and predictors of pharmaceutical
treatment class choice among US patients diagnosed with Parkinson’s Disease
(PD).METHODS:This retrospective study utilized data from the MarketScan Claims
and Encounters database over the period from 1/1/2006 through 12/31/2011. Pa-
tients were included in the study if they were diagnosed with PD (with first such
date identified as index date), were at least 35 years old, had continuous insurance
coverage from 6 months prior through 12 months post index date, and received a
post-period prescription a medication for one of the following anti-PD classes:
dopamine agonist (DA), MAO-B inhibitor (MAO-B) or levodopa (LD). The study con-
sisted of descriptive analyses comparing the cohorts and logistic regressions ex-
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amining predictors of medication class prescribed. RESULTS: There were 4,916
individuals in the study (1,788 in DA cohort, 646 in MAO-B, and 2,482 in LD). Results
of the logistic regression revealed that older patients were significantly less likely
to receive DA (OR0.977; 95% CI 0.966-0.988) or a MAO-B (OR0.968; 95% CI0.954-
0.983), compared to LD. Compared to LD cohort, patients who receive a MAO-B were
significantly less likely to be diagnosed with pre-period depression (OR0.540; 95%
CI 0.310-0.940) and patients who received a MAO-B or DA were significantly less
likely to be diagnosed with psychoses (MAO-B - OR0.220; 95% CI 0.105-0.459: DA –
OR0.732; 95% CI 0.542-0.989). Furthermore, results revealed that patients diag-
nosed by a neurologist were significantly more likely to receive a DA (OR1.651;
95% CI 1.353-2.014) or a MAO-B (OR1.607; 95% CI 1.193 – 2.165), compared to LD.
Region of residence and health plan membership were also found to predict initial
medication class. CONCLUSIONS: These analyses indicate that patient character-
istics, health status, diagnosing physician and access disparities all impact initial
therapeutic class of medication prescribed for patients with PD.
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OBJECTIVES: During 2007-2011 Multiple Sclerosis (MS) was the only category that
experienced triple digit growth in sales, leading to doubling of their sales from $3.4
billion in 2007 to $7 billion in 2011. This has led to change in payer coverage and
utilization of branded MS products. This study was undertaken to understand
current trends in sales, access and utilization management for MS products in the
United States. METHODS: Sales data for MS branded products was analyzed using
IMS Health 2007-2011 data. Access and utilization management trends were ana-
lyzed using preferred drug list and coverage policies of top US health plans. Primary
discussions were conducted with pharmacy and medical directors to understand
new trends in coverage of MS products. RESULTS: More than half (approximately
59%) of the branded MS products are covered by health plans as non-preferred
products or at Tier 3/4 . Significant majority (84%) of these products were covered
with prior authorization or pre-certification criteria. Quantity limits were used by
34% of the plans. Use of step therapy or progression prescription is not currently
common and was found in only 5% of the plans. In this sample (n37), only one
plan ( 5%) had formulary exclusion for an MS product. Payer designated specialty
pharmacies are increasingly being used by various health plans. Compared to 2007,
payer coverage of MS products shows significant increase in use of PA (40% in 2007
versus 84% in 2012). Payers express high concern for rapidly growing MS category
and report use of more utilization management approaches to control spending.
CONCLUSIONS: MS products are facing more aggressive utilization management.
Patient access for new MS therapies could be limited due to non-preferred status,
high co-pay or strict PA criteria.
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OBJECTIVES: To map the health care utilization of multiple sclerosis (MS) patients
incl. MS-specific drug therapy in the ambulatory setting of the Statutory Health
Insurance (SHI) system in Bavaria/Germany. METHODS: Pseudonymised adminis-
trative claims data of the SHI-accredited physicians in Bavaria/Germany (April 2005
– December 2009) were used. Patients with at least one MS diagnosis (ICD-10 G35)
documented by a neurologist or psychiatrist or at least one disease modifying drug
(DMD) prescription (interferon beta-1(a/b), glatirameracetat, or natalizumab). All
cases of outpatient medical services with an MS diagnosis were considered. Anal-
ysis of MS-associated drug therapy included DMD, drugs used for symptomatic
relief and systemic corticosteroids for relapse therapy. Persistence (duration of
continuous prescription) and medication possession ratio (MPR; percentage of days
covered by medication) were calculated for DMD. RESULTS: The annual number of
MS patients ranged from n12.800 (2005) to n18.200 (2009). The proportion of
patients with at least one DMD prescription (interferon beta, glatirameracetat, na-
talizumab, azathioprin) increased from 46% (2005) to 51% (2009). The average per-
sistence for these drugs (excl. natalizumab) varied between 12 months (glatiram-
eracetat) and 14 months (interferons). The median MPR varied between 0,69
(natalizumab) and 0,84 (interferon beta 1-a) in the first year following the index
prescription. Mostly, these drugs were prescribed by neurologists. In total, 10,060
patients receiving systemic corticosteroids for the therapy of relapse were identi-
fied between 2005 and 2009. The average number of such therapies per year and
patient was about 1.5. The percentage of patients with relevant MRI scans (neuro-
cranium / spinal cord) was substantial higher in patients with relapse therapies
compared with patients without such therapy. CONCLUSIONS: The analysis indi-
cated (1) an increase of disease prevalence but also of patients supplied with DMD
between 2005 and 2009 and (2) the importance of neurologists within the MS treat-
ment.
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OBJECTIVES: To identify and explore how reimbursement decisions for natali-
zumab, a treatment for multiple sclerosis (MS), were overturned from an initial
rejection to a recommendation. METHODS: This analysis was conducted in con-
juntion with a wider review of the global reimbursement landscape for MS thera-
pies. We reviewed reimbursement decisions or recommendations from global
payer decision-making agencies, including any decisions where an initial rejection
was overturned. We reviewed the agency rationale for both the original and sub-
sequent decisions, and how the manufacturer influenced the decision reversal.
RESULTS: Since 2006, 17 payer decisions for natalizumab were identified (six rec-
ommendations, eight restricted recommendations and three rejections). The three
rejected decisions were later overturned by the manufacturer submitting further
evidence. To PBAC this involved re-defining the indirect comparison to consider
the heterogeneity in the trials included. To SMC and CADTH post-hoc analysis was
submitted for the specific subgroup of rapidly evolving severe relapsing remitting
MS. For CADTH a 15% price discount was agreed in addition. Across all agencies
clinical need was an important factor. CONCLUSIONS: By emphasising unmet
needs, submitting further evidence in defined subgroups and ensuring indirect
comparisons are methodologically sound, it has been possible to overturn initial
negative decisions by payer agencies to restricted recommendations in define sub-
group. Identification of the optimum treatable population has proved pivotal in the
reversal of fortune.
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OBJECTIVES: There is conflicting evidence in published literature regarding the
association between montelukast and neuropsychiatric disturbances. We sought
to determine if the use of montelukast was associated with neuropsychiatric dis-
turbances in children with Asthma.METHODS:A 10% sample of the LifeLink health
plan claims data was used to identify subjects less than 18 years of age with a
primary diagnosis of asthma between Jan 1, 1998 and Dec 31, 2009. Multiple case
definitions for neuropsychiatric disturbances were formulated ranging from nar-
row to broad measures based on the diagnoses of neuropsychiatric related disor-
ders or use of a psychotropic medication. We used a nested case control design and
each case was matched to 3 controls on age, gender and geographic region and
controls were assigned an index date based on the matched case. Exposure to
montelukast was measured as any exposure during the year, recency of exposure,
cumulative duration of exposure and cumulative dose of exposure during the 30
days and 365 days prior to the outcome. Conditional logistic regression was used to
estimate the unadjusted and the adjusted odds ratios after controlling for
confounders. RESULTS: Using the broadest definition for neuropsychiatric distur-
bances, 1,920 cases and 5,760 matching controls were identified. Cases were more
likely to be diagnosed with epilepsy, diabetes, cancer and hypothyroidism, and
were more likely to use inhaled corticosteroids, long-acting beta2-agonists, sys-
temic corticosteroids and metoclopramide. Subjects exposed to montelukast dur-
ing the year had an unadjusted OR of 1.085 (CI 0.962 – 1.223) and an adjusted OR of
1.032 (CI 0.909 – 1.172) for experiencing a neuropsychiatric disturbance. None of the
other montelukast exposure measures showed a positive association except a cu-
mulative dose of exposure between 351mg and 900mg (OR1.308; CI: 1.082 – 1.581).
CONCLUSIONS: Preliminary results do not suggest a consistent positive associa-
tion between montelukast and neuropsychiatric disturbances.
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OBJECTIVES: COPD is an important cause of morbidity and mortality. Statistics
Korea presented in 2009 the mortality of COPD was 9.4 per one hundred thousand
marking the disease as one of the 10 major death causes in Korea. This study was
performed to investigate epidemiologic data especially incidence and risk factors
associated with COPD exacerbations in Korea.METHODS: A retrospective observa-
tional study was carried out on 1,112 COPD patients from 47 medical centers
throughout Korea. The data collection was performed at enrollment and a past year
from the enrollment. The COPD patients were defined by GOLD criteria 2010. Also
we investigated demographic characteristics, COPD exacerbation, Lung function
Test, Comorbidity, COPD assessment test (CAT), and COPD medication. RESULTS:
Among 1,112 patients, more than half of the respondents were more than 70 years
old, 91% (n1,011) were male, mean BMI was 22.2 (SD 3.3) kg/m2, mean COPD
duration was 5.8 years, and 55.5% (n616) were classified as chronic bronchitis. The
occurrence of exacerbation was 35.4% (n394), the mean frequency of exacerba-
tion in past year was 0.67 (SD1.28), and decrease of FEV1/FVC results align with
GOLD stage was statistically significant (p0.0001). The most frequently reported
comorbidities were hypertension (36.0%, n400) and bronchial asthma (16.6%,
n185). Mean CAT sum score was 16.8 (SD 8.3). The most frequently used COPD
medication was long-acting muscarinic antagonist (47.9%). Multivariate logistic
regression results show the effect on exacerbation in the subjects who had only
pulmonary emphysema was 0.7 times than the subjects who had only chronic
bronchitis (95%CI [0.49-0.96], p-value0.001), and subjects with history of pneumo-
nia were 11.1 times higher than in the subjects without history of pneumonia (95%
CI [6.89-17.87], p-value0.0001). CONCLUSIONS: Our results suggested that the
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